ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1669954
Artificial Neural Network-Augmented Dosiomic Integration for Predicting Distant Recurrence in NSCLC patients Treated with SBRT
Provisionally accepted- 1SUNY Upstate Medical University Upstate Department of Radiation Oncology, Syracuse, United States
- 2University of Florida, Gainesville, United States
- 3Indian Institute of Technology Roorkee, Roorkee, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Stereotactic body radiotherapy (SBRT) is a standard curative treatment for inoperable early-stage non-small cell lung cancer (NSCLC) patients. However, the high rate of distant recurrence following radiotherapy remains a significant clinical challenge. This study focuses on developing a machine learning model for distant recurrence prediction using diverse dosiomic and patient-specific clinical features. The proposed model aims to assist clinicians in informed decision-making, individualized treatment decisions to improve post-SBRT outcomes. Method: This study utilized a multi-institutional dataset comprising 575 NSCLC patients who underwent SBRT. A total of 21 features, comprising 14 dosimetric and 7 clinical variables, were incorporated for developing the predictive framework. The predictive model was developed based on an artificial neural network (ANN) architecture with several dense layers. Model training and internal validation were conducted using data obtained from one institution, while external validation was performed utilizing data from an independent institution. To enhance clinical interpretability, SHAP analysis was employed to evaluate the relative importance of each feature contributing to the model's output. Results: The initial predictive model, developed using individual clinical and dosimetric features, achieved area under the receiver operating characteristic curve (ROC-AUC) in the range of 0.64 to 0.65 while validated with an external dataset, respectively. To enhance predictive performance, dosimetric features were integrated with clinical variables, resulting in improved ROC-AUC values of 0.75 for internal validation with 10-fold cross validation technique and 0.71 for external validation with 1000 bootstrap iterations. Dosiomic features enhanced performance by 9-16%, highlighting their importance in distant recurrence prediction. Additionally, to enhance the interpretability of the model's predictions, SHAP-based analysis was conducted, revealing that the number of treatment fractions, dose per fraction, and minimum dose to GTV were among the five most influential dosiomic features. Conclusion: This study introduces an ANN-based model for predicting distant recurrence in NSCLC patients followed by SBRT. This study also demonstrates the impactful dosimetric and clinical features for the designed predictive model, highlighting its potential as an assistive tool for informed and individualized treatment planning in clinical practice.
Keywords: artificial neural network, machine learning, Treatment Response Modeling, SBRT, NSCLC, Distant recurrence
Received: 20 Jul 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 Halder, Alden, Podder, Orlando, Mix, Biswas, Bogart and Podder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tarun Podder, tkpodder@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.